Growing Mid-Tier Pharmaceutical Company Awards $1.4 Million Late Phase Study to eResearchTechnology
June 14 2005 - 9:07AM
PR Newswire (US)
Growing Mid-Tier Pharmaceutical Company Awards $1.4 Million Late
Phase Study to eResearchTechnology Agreement Illustrates Continued
Trend Toward Robust Phase III Cardiac Safety Monitoring Following
the Finalization of International Regulatory Guidance PHILADELPHIA,
June 14 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT)
(NASDAQ:ERES), a leading provider of centralized
electrocardiographic (ECG) collection and interpretation services,
announced today that it has been awarded about $1.4 million in
cardiac safety monitoring and services for a late phase development
program from a growing mid-tier pharmaceutical for one of its key
new drug candidates in development. The award covers a significant
Phase III study. eRT will perform digital collection, measurement,
interpretation, review, and distribution of cardiac safety data
through its EXPeRT workflow enabled data handling technology, the
first solution in production that was designed explicitly to meet
emerging international regulatory guidance and technical standards.
"This award is illustrative of the robust cardiac safety monitoring
in later phase clinical development that is referenced in the
recently finalized international regulatory guidance," said Scott
Grisanti, senior vice president of business development and chief
marketing officer at eRT. "eRT is uniquely equipped to meet the
full range of cardiac safety services required by today's drug
development community - from extensive later phase programs, as
represented by this contract, to focused Thorough QT studies."
Based in Philadelphia, PA, eResearchTechnology, Inc.
(http://www.ert.com/) is a provider of technology and services to
the pharmaceutical, biotechnology and medical device industries on
a global basis. The company is a market leader in providing
centralized core-diagnostic electrocardiographic (ECG) technology
and services to evaluate cardiac safety in clinical development.
The company is also a leader in providing technology and services
to streamline the clinical trials process by enabling its customers
to automate the collection, analysis, and distribution of clinical
data in all phases of clinical development. Statements included in
this release may constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as
competitive factors, technological development, market demand, and
the company's ability to obtain new contracts and accurately
estimate net revenues due to variability in size, scope and
duration of projects, and internal issues in the sponsoring client.
The sponsor may cancel this agreement at its sole discretion. As a
result, actual results may differ materially from any financial
outlooks stated herein. Further information on potential factors
that could affect the company's financial results can be found in
the company's Reports on Form 10-K and 10-Q filed with the
Securities and Exchange Commission. DATASOURCE:
eResearchTechnology, Inc. CONTACT: Joan Sterlacci of
eResearchTechnology, +1-908-203-6473 or Matt Hayden of Hayden
Communications, +1-858-704-5065 Web site: http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles